Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Breast Cancer Research and Treatment

• Publication date

  1999-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1006262324959PMID 10481944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy

  2005cited by this paper
• Do we really need prognostic factors for breast cancer?

  2004cited by this paper
• Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma

  2004cited by this paper
• Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.

  1996cited by this paper
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

  1996cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma

  1995cited by this paper
• Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.

  1994cited by this paper
• Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.

  1994cited by this paper
• Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma : immunocytochemical hormone receptors and prognostic factors

  1994cited by this paper
• The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

  1994cited by this paper
• Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study.

  1993cited by this paper
• Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

  1993cited by this paper
• Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team.

  1993cited by this paper
• p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

  1993cited by this paper
• Potential immunogenicity of oncogene and tumor suppressor gene products.

  1993cited by this paper
• Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression

  1992cited by this paper
• Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections

  1992cited by this paper
• Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

  1992cited by this paper
• Prognostic factors and treatment decisions in axillary-node-negative breast cancer.

  1992cited by this paper
• Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors

  1991cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The Geometric Interpretation of Correspondence Analysis

  1987cited by this paper
• Benzecri jp. Histoire et prehistoire de l'analyse des donees. Dunod, paris, 1982

  1987cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper

• Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue

  2022cites this paper
• Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer

  2018cites this paper
• (2008) Cancer profiles by affinity propagation. In: Seventh International Conference on Machine Learning and Applications, 2008.

  2017cites this paper
• HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis

  2016cites this paper
• Prognostic Significance of Deregulated Dicer Expression in Breast Cancer

  2013cites this paper
• Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

  2013cites this paper
• Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer

  2012cites this paper
• Identification of prognostic targets in breast cancer using immunohistochemical and in situ hybridisation methodologies

  2011cites this paper
• Expression of P53 Oncoprotein in Human Breast Ductal Carcinoma (Imam Susilo) 130 EXPRESSION OF P53 ONCOPROTEIN IN HUMAN BREAST DUCTAL CARCINOMA (IN SITU, INVASIVE AND METASTATIC)

  2010cites this paper
• Novel methods to elucidate core classes in multi-dimensional biomedical data

  2010cites this paper
• Noninvasive Imaging of Breast Cancer

  2009cites this paper
• T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

  2009cites this paper
• Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

  2009cites this paper
• Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer.

  2008cites this paper
• Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa

  2008cites this paper
• Az antitestfüggő sejtközvetített citotoxicitás (ADCC) szerepe a trastuzumab hatásmechanizmusában

  2008cites this paper
• Cancer Profiles by Affinity Propagation

  2008cites this paper
• Η έκφραση των υποδοχέων της τάξης HER στον καρκίνο του μαστού και βιολογική συμπεριφορά των καρκινικών κυττάρων

  2007cites this paper
• Relationship between p53 and p27 expression following HER2 signaling.

  2007cites this paper
• Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods

  2006cites this paper
• ERBB FAMILY IN BREAST CANCER: DETECTION METHODS, CLINICAL AND PROGNOSTIC SIGNIFICANCE, UNDER-RECOGNIZED MECHANISMS IN THEIR FUNCTION

  2006cites this paper
• ErbB2 overexpression in p53‐inactivated mammary epithelial cells

  2006cites this paper
• The future perspectives of breast cancer therapy.

  2006cites this paper
• Different patterns of inflammation and prognosis in invasive carcinoma of the breast

  2006cites this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cites this paper
• Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling.

  2005cites this paper
• Predominance of high-grade pathway in breast cancer development of Middle East women

  2005cites this paper
• Analysis of T-Cell Clonality Pattern in Tumor Samples of Breast Cancer Patients

  2005cites this paper
• Analysis of T-cell clonality pattern in tumor samples of breast cancer patients.

  2005cites this paper
• Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.

  2004cites this paper
• A Viral Aetiology for Breast Cancer: Time to Re-Examine the Postulate

  2004cites this paper
• Immunological and pathobiological roles of fibulin-1 in breast cancer

  2004cites this paper
• A human murine mammary tumour virus‐like agent is an unconvincing aetiological agent for human breast cancer

  2004cites this paper
• Antibodies

  2004cites this paper
• Immunological and pathobiological roles of fibulin-1 in breast cancer

  2004cites this paper
• Role of HER receptors family in development and differentiation

  2004cites this paper
• Antitumor Antibodies: From Research to Clinic

  2004cites this paper
• Elevated Expression of the Tumor Suppressing Protein p53 is Associated with the Presence of Mouse Mammary Tumor-Like env Gene Sequences (MMTV-like) in Human Breast Cancer

  2004cites this paper
• Hereditary serous ovarian carcinogenesis, a hypothesis

  2004cites this paper
• Role of hormonal risk factors in HER2-positive breast carcinomas

  2003cites this paper
• Naturally occurring B-cell responses to breast cancer

  2003cites this paper
• Role of proliferation in HER2 status predicted response to doxorubicin

  2003cites this paper
• HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

  2002cites this paper
• SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.

  2002cites this paper
• Ductal Carcinoma in Situ of the Breast: a New Phenotype Classification System and its Relation to Prognosis

  2002influential citation
• HER2 as a Prognostic Factor in Breast Cancer

  2001cites this paper
• Role of p53 in HER2-induced Proliferation or Apoptosis*

  2001cites this paper
• Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

  2001cites this paper
• The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker.

  2001cites this paper
• HER2 TESTING RECOMMENDATIONS IN AUSTRALIA

  2001cites this paper
• The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker.

  2001cites this paper
• On the birth of breast cancer.

  2001cites this paper
• Identification of a proviral structure in human breast cancer.

  2001cites this paper
• Standard medical treatment for early breast cancer.

  2001cites this paper
• The response of the surgeon to changing patterns in breast cancer diagnosis.

  2001cites this paper
• HER2/neu as a predictive factor in breast cancer.

  2001cites this paper
• Pan Arab Journal of Oncology

  year unknowncites this paper